Table 1.
The potential drug resistance driver genes.
| Gene | RNA-seq (FC, FDR ≤ 0.05) | Closest DMS and distance (Kbp) | RRBS (meDiff%, qval ≤ 0.05) | Previous Links to Ovarian Cancer | |
|---|---|---|---|---|---|
| Sens 0 μM vs Res 0 μM | Res 0 μM vs Res 7 μM | Sens 0 μM vs Res 0 μM | |||
| AQP3 | 5.9 | −1.86 | chr9:36166020–2,725 | −70 | Regulates cell migration in EGF dependent manner18 |
| CTSB | 5.09 | −1.84 | chr8:10897405–803 | −50 | Unfavorable marker for survival19 |
| CYP24A1 | 259.33 | −2.18 | chr20:52556813–213 | −67 | Increased expression20, 21 |
| PRSS56 | −2.94 | −2.38 | chr2:232290776–1,094 | −57 | — |
| ECEL1 | −3.46 | −2.06 | chr2:232290776 1,054 | −57 | Chemotherapy-resistance22 |
| SPOCK1 | −3.29 | −2.65 | chr5:133477187 2,834 | −54 | Growth and metastasis23 |
| SYNE1 | −2.17 | −2.22 | chr6:156200288–3,242 | −71 | Mutations predictive for malignant transformation24, 25 |
| PBX1 | −2.09 | −1.97 | chr1:164500920–28 | −46 | Mediated survival in response to Notch326 |
| PTGDS | −3.79 | −2.08 | chr9:136310987 168 | 68 | Chemoresistance33 |
| ST3GAL5 | −2.41 | −2.02 | chr2:85892782 173 | −37.61 | Decreased expression27 |
| FOSL1 | 1.98 | 1.98 | chr11:65682138–14 | −43 | ER-dependent induction impaired in response to saracatinib+/− fulvestrant28 |
| IL8/CXCL8 | 1.74 | 2.14 | chr4:68449172–6,157 | −44 | Chemoresistance33 |
| ARRDC4 | 1.95 | 2.1 | chr15:98937633 421 | 47 | — |
| TNFAIP3 | 3.33 | 2.46 | chr:136929632–1,259 | −63 | Induced by ARID3B29 |
| ODC1 | 2.05 | 1.94 | chr2:10445016 136 | −65 | Downregulated in response to platinium drugs30 |
| RNF43 | 3.63 | 1.66 | chr17:55185542 1,245 | −34 | Tumor supressor and mutation hotspot51, 52 |
| HERC5 | 2.41 | 1.74 | chr4:68449172–20,929 | −44 | — |
| OASL | 4.99 | 1.93 | chr12:121177842 280 | −56 | Chemoresistance33 |
| KLF4 | 5.21 | 2.28 | chr9:115618930–5,367 | −48 | Downregulated and regulates BCL2/Bax ratio53, mediates EMT54 |
| IL6 | 16.27 | 1.8 | chr7:30737735–7,971 | −47 | Chemoresistance33, potential prognostic marker32, 34 |